Yutaka Suehiro

Dr. Yutaka Suehiro


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2017 in Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
YYYuko Yamaoka
Yuko Yamaoka
YSYutaka Suehiro
Yutaka Suehiro
SHShinichi Hashimoto
Shinichi Hashimoto
THTomomi Hoshida
Tomomi Hoshida
MFMichiyo Fujimoto
Michiyo Fujimoto
TYTakahiro Yamasaki
Takahiro Yamasaki

28 September 2016 in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
Verified
Journal Article
Open access
YSYutaka Suehiro
Yutaka Suehiro
KSKouhei Sakai
Kouhei Sakai
MNMitsuaki Nishioka
Mitsuaki Nishioka
SHShinichi Hashimoto
Shinichi Hashimoto
TTTaro Takami
Taro Takami
TYTakahiro Yamasaki
Takahiro Yamasaki
Accumulating evidence shows an over-abundance of Fusobacterium nucleatum in colorectal tumour tissues. Although stool DNA testing of Fusobacterium nucleatum might be a potential marker for the detection of colorectal tumours, the difficulty in detecting Fusobacterium nucleatum in stool by conventional methods prevented further explorations. Therefore, we developed a droplet digital polymerase chain reaction (PCR) assay for detecting Fusobacterium nucleatum in stool and investigated its clinical utility in the management of colorectal tumours in a Japanese population. Feces were collected from 60 healthy subjects (control group) and from 11 patients with colorectal non-advanced adenomas (non-advanced adenoma group), 19 patients with colorectal advanced adenoma/carcinoma in situ (advanced adenoma/carcinoma in situ (CIS) group) and 158 patients with colorectal cancer of stages I to IV (colorectal cancer group). Absolute copy numbers of Fusobacterium nucleatum were measured by droplet digital PCR. The median copy number of Fusobacterium nucleatum was 17.5 in the control group, 311 in the non-advanced adenoma group, 122 in the advanced adenoma/CIS group, and 317 in the colorectal cancer group. In comparison with that in the control group, the Fusobacterium nucleatum level was significantly higher in the non-advanced adenoma group, the advanced adenoma/CIS group and the colorectal cancer group. This study illustrates the potential of stool DNA testing of Fusobacterium nucleatum by droplet digital PCR to detect individuals with colorectal tumours in a Japanese population.

29 May 2018 in Cancers
Verified
Journal Article
Open access
PDF file
JNJun Nishikawa
Jun Nishikawa
HIHisashi Iizasa
Hisashi Iizasa
Hironori YoshiyamaHironori Yoshiyama
Hironori Yoshiyama
KSKanami Shimokuri
Kanami Shimokuri
YKYuki Kobayashi
Yuki Kobayashi
ISIsao Sakaida
Isao Sakaida
Epstein–Barr virus-associated gastric carcinoma (EBVaGC) is the most common malignancy caused by EBV infection. EBVaGC has definite histological characteristics similar to gastric carcinoma with lymphoid stroma. Clinically, EBVaGC has a significantly low frequency of lymph node metastasis compared with EBV-negative gastric cancer, resulting in a better prognosis. The Cancer Genome Atlas of gastric adenocarcinomas proposed a molecular classification divided into four molecular subtypes: (1) EBVaGC; (2) microsatellite instability; (3) chromosomal instability; and (4) genomically stable tumors. EBVaGC harbors a DNA methylation phenotype, PD-L1 and PD-L2 overexpression, and frequent alterations in the PIK3CA gene. We review clinical importance of EBVaGC and discuss novel therapeutic applications for EBVaGC.

7 November 2014 in Cancers
Verified
Journal Article
Open access
PDF file
JNJun Nishikawa
Jun Nishikawa
Hironori YoshiyamaHironori Yoshiyama
Hironori Yoshiyama
HIHisashi Iizasa
Hisashi Iizasa
YKYuichi Kanehiro
Yuichi Kanehiro
MNMunetaka Nakamura
Munetaka Nakamura
ISIsao Sakaida
Isao Sakaida
The Epstein-Barr virus (EBV) is detected in about 10% of gastric carcinoma cases throughout the world. In EBV-associated gastric carcinoma, all tumor cells harbor the clonal EBV genome. Gastric carcinoma associated with EBV has distinct clinicopathological features, occurs predominately in men and in younger-aged individuals, and presents a generally diffuse histological type. Most cases of EBV-associated gastric carcinoma exhibit a histology rich in lymphocyte infiltration. The immunological reactiveness in the host may represent a relatively preferable prognosis in EBV-positive cases. This fact highlights the important role of EBV in the development of EBV-associated gastric carcinoma. We have clearly proved direct infection of human gastric epithelialcells by EBV. The infection was achieved by using a recombinant EBV. Promotion of growth by EBV infection was observed in the cells. Considerable data suggest that EBV may directly contribute to the development of EBV-associated GC. This tumor-promoting effect seems to involve multiple mechanisms, because EBV affects several host proteins and pathways that normally promote apoptosis and regulate cell proliferation.

1 June 2008 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
YSYutaka Suehiro
Yutaka Suehiro
TOToshiyuki Okada
Toshiyuki Okada
TOTakae Okada
Takae Okada
KAKeiko Anno
Keiko Anno
NONaoko Okayama
Naoko Okayama
YHYuji Hinoda
Yuji Hinoda
Purpose: Many investigators have reported that aneuploidy detected by flow cytometry is a useful prognostic marker in patients with endometrial cancer. Laser scanning cytometry (LSC) is a technology similar to flow cytometry but is more feasible for clinical laboratory use. We evaluated the usefulness of DNA ploidy detected by LSC as a prognostic marker in patients with endometrial cancer and investigated genetic and epigenetic factors related to aneuploidy. Experimental Design: Endometrial cancer specimens from 106 patients were evaluated. The methylation status of CDH13, Rassf1, SFRP1, SFRP2, SFRP4, SFRP5, p16, hMLH1, MGMT, APC, ATM, and WIF1 and mutations in the p53 and CDC4 genes were investigated. LSC was carried out to determine DNA ploidy. Fluorescence in situ hybridization was done with chromosome-specific centromeric probes to assess chromosomal instability. Results: Univariate and multivariate analyses revealed that p53 mutation and lack of CDH13 hypermethylation associated positively with aneuploidy. Univariate analysis showed that aneuploidy, chromosomal instability, and lack of CDH13 hypermethylation as well as surgical stage were significantly predictive of death from endometrial cancer. Furthermore, multivariate analysis revealed that stage in combination with either DNA aneuploidy or lack of CDH13 hypermethylation was an independent prognostic factor. Conclusion: These results suggest that analysis of DNA ploidy and methylation status of CDH13 may help predict clinical outcome in patients with endometrial cancer. Prospective randomized trials are needed to confirm the validity of an individualized approach, including determination of tumor ploidy and methylation status of CDH13, to management of endometrial cancer patients.

19 June 2014 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
YSYoshitaro Shindo
Yoshitaro Shindo
Shoichi HazamaShoichi Hazama
Shoichi Hazama
YMYoshinari Maeda
Yoshinari Maeda
HMHiroto Matsui
Hiroto Matsui
MIMichihisa Iida
Michihisa Iida
MOMasaaki Oka
Masaaki Oka
We previously reported the clinical efficacy of adoptive immunotherapy (AIT) with dendritic cells (DCs) pulsed with mucin 1 (MUC1) peptide and cytotoxic T lymphocytes (CTLs). We also reported that gemcitabine (GEM) enhances anti-tumor immunity by suppressing regulatory T cells. Therefore, in the present study, we performed combination therapy with AIT and GEM for patients with unresectable or recurrent pancreatic cancer.